Recent insights into experimental mouse models of diabetic nephropathy

Nephron - Experimental Nephrology

Volumn 104, Issue 2, 2006, Pages

  Tesch, Gregory H ^a,b   Nikolic Paterson, David J ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products; C57BL 6; db db; Diabetic nephropathy; Fibrosis; Mouse models; Oxidative stress; Streptozotocin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; APOCYNIN; CATALASE; CYTOKINE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; IMATINIB; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; PEROXIREDOXIN; PEROXYNITRITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMAD2 PROTEIN; SMAD3 PROTEIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXPERIMENTAL MOUSE; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLOMERULOSCLEROSIS; INBRED STRAIN; INFLAMMATION; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FIBROSIS; KIDNEY INJURY; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; SHORT SURVEY; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; MICE;

EID: 33748999280     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093998     Document Type: Short Survey

References (34)

1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW, American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004;27(suppl 1):S79-S83.
2. Svensson M, Sundkvist G, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Henricsson M, Nystrom L, Torffvit O, Waernbaum I, Ostman J, Eriksson JW: Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003;26:2903-2909.
3. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: AMDCC: mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45.
4. Allen TJ, Cooper ME, Lan HY: Use of genetic mouse models in the study of diabetic nephropathy. Curr Atheroscler Rep 2004;6:197-202.
5. Qi Z, Fujita H, Jin J, Davis LS, Wang LS, Wang Y, Fogo AB, Breyer MD: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005;54:2628-2637.
6. Janssen U, Phillips AO, Floege J: Rodent models of nephropathy associated with type II diabetes. J Nephrol 1999:12;159-172.
7. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004:25;971-1010.
8. Konrad RJ, Mikolaenko I, Tolar JF, Liu K, Kudlow JE: The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic β-cell O-GlcNAc-selective N-acetyl-β-β-D-glucosaminidase. Biochem J 2001;356:31-41.
9. Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DC: Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int 2005;68:391-398.
10. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004;19:2987-2996.
11. De Haan JB, Stefanovic N, Nikolic-Paterson DJ, Scurr LL, Croft KD, Mori TA, Hertzog P, Kola I, Atkins RC, Tesch GH: Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Renal Physiol 2005;28:F544-F551.
12. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM: Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 2006;290:F214-F222.
13. Lassila M, Seah ICK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004;15:2125-2138.
14. Lassila M, Jandeleit-Dahm KA, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16:363-373.
15. Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233.
16. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004;65:116-128.
17. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH: ICAM-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005;16:1711-1722.
18. DeRubertis FR, Craven PA, Melhem MF, Salah EM: Attentuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 2004;53:762-768.
19. Kumar S, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003;284:F1138-F1144.
20. Cohen MP, Masson N, Hud E, Ziyadeh F, Han DC, Clements RS: Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 2000;8:135-143.
21. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
22. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R: Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004;53:166-172.
23. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137.
24. Craven PA, Melhem MF, Phillips SL, DeRubertis FR: Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001;50:2114-2125.
25. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, Lei XG: Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004;101:8852-8857.
26. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, Tesch GH: Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004;47:1210-1222.
27. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006;69:73-80.
28. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003;52:2586-2593.
29. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
30. Kim HW, Kim BC, Song CY, Kim JH, Hong HK, Lee HS: Heterozygous mice for TGF-beta-IIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int 2004;66:1859-1865.
31. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE: Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003;14:968-980.
32. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297-1307.
33. Shibuya K, Kanasaki K, Isono M, Sato H, Omato M, Sugimoto T, Araki S, Isshiki K, Kashiwagi A, Haneda M, Koya D: N-acetylseryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005;54:838-845.
34. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M: SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol DOI:10.1152/ajprenal.00357.2005.